Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Sumana Sharma is one of the founding partners of a major new pan-European initiative that aims to transform how scientists identify and target cancer's weaknesses, moving beyond simply mapping cancer vulnerabilities towards predicting them before they are experimentally tested.

© Adobe Stock

The PRECISE consortium (Predictive Relationships Explaining Cancer Genetic Interactions and Synthetic Essentiality) brings together more than 30 experimental and computational research groups from over 20 institutes and universities across nine European countries. The consortium's vision is outlined in a Nature Genetics commentary, marking the formal launch of the collaboration.

At the MRC Weatherall Institute of Molecular Medicine, Dr Sumana Sharma is among the researchers contributing to the consortium. PRECISE will combine functional genomics, multimodal molecular profiling and artificial intelligence to build predictive models that explain why cancers become dependent on particular genes or pathways and identify new therapeutic opportunities in previously untested settings.

Speaking about the consortium, Sumana said:

This is an exciting time for cancer vulnerability prediction. We are moving beyond simple growth-based assessments towards a deeper understanding of context-specific dependencies that drive tumour biology. International collaborations such as the PRECISE consortium are essential for accelerating this shift, enabling us to identify and target cancer vulnerabilities from the outset through the integration of expertise, data, and technologies across Europe.

Unlike existing cancer dependency maps, which largely describe vulnerabilities that have already been observed, PRECISE will use an iterative prediction-validation approach. Computational models will guide laboratory experiments, with the resulting data feeding back into improved predictions. The long-term goal is to develop generalisable rules that can anticipate cancer vulnerabilities across different tumour types and biological contexts, ultimately helping to expand precision oncology to patients whose cancers currently lack actionable treatment options.

The PRECISE consortium is also committed to open science. The consortium promotes common experimental standards, interoperable analytical pipelines, and FAIR (Findable, Accessible, Interoperable and Reusable) data principles to ensure that datasets and computational tools can be shared, integrated, and reused across the international research community.

 

Further information about the consortium, its principles and its goals is available on the PRECISE web portal.

 

Similar stories

New technology helps decode the genetic changes behind disease

RDM researchers have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Professor Marella de Bruijn receives MRC Programme Award

Congratulation to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.

How body fat is stored across organs may reveal hidden health risks, study suggests

University of Oxford researchers have found that how fat accumulates in the body is just as important for identifying different health risks as a person’s overall weight.

Professor KJ Patel awarded Royal Society Buchanan Medal

Congratulations to Professor Patel, who has received the Buchanan Medal, which recognises distinguished contributions to the biomedical sciences.

New pump-priming awards support cross-cutting research across RDM

Five Radcliffe Department of Medicine research teams have secured pump-priming funding to support new collaborations and early-stage research aligned with RDM’s cross-cutting research themes.

Similar stories

New technology helps decode the genetic changes behind disease

RDM researchers have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Professor Marella de Bruijn receives MRC Programme Award

Congratulation to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.

How body fat is stored across organs may reveal hidden health risks, study suggests

University of Oxford researchers have found that how fat accumulates in the body is just as important for identifying different health risks as a person’s overall weight.

Professor KJ Patel awarded Royal Society Buchanan Medal

Congratulations to Professor Patel, who has received the Buchanan Medal, which recognises distinguished contributions to the biomedical sciences.

New pump-priming awards support cross-cutting research across RDM

Five Radcliffe Department of Medicine research teams have secured pump-priming funding to support new collaborations and early-stage research aligned with RDM’s cross-cutting research themes.